Skip to content
Toggle main navigation
EndoForum logo
EndoForum logo
  • Join Today
    Log in
    Select an available language
    EN

    Endocrine News

    Endocrine News provides an in-depth look at trends in the field of endocrinology as well as a closer look at recently published research.

    Filter by category
    All
    Adrenal
    Advocacy
    Bone and Mineral
    Cardiometabolic
    Clinical
    COVID-19
    Diabetes
    Diabetes News and Research
    Diabetes Research Articles
    Early Career Corner
    See all

    Results (12)

    Beyond the Sensor

    Beyond the Sensor

    From customizable glucose alerts and remote data sharing to integrated clinical reporting, digital platforms are transforming how patients and healthcare professionals access and use diabetes technology. Continuous glucose monitoring (CGM) has become an integral part of diabetes management, but innovation is extending well beyond the sensors themselves. Companion applications and digital health pl
    November 18, 2026
    Charting the Future of Endocrine Care

    Charting the Future of Endocrine Care

    From tracking complex patient data to simplifying everyday workflows, today’s EHR platforms are transforming how endocrinologists manage their practices and patient care. For endocrinologists, an electronic health record (EHR) has to do more than house patient charts. The right platform can help clinicians follow years of laboratory trends, manage diabetes technology data, monitor medications and
    September 24, 2026
    Rise of Machine Learning: AI’s Role in Approaching Congenital Disorders of Adrenal Steroidogenesis

    Rise of Machine Learning: AI’s Role in Approaching Congenital Disorders of Adrenal Steroidogenesis

    A commentary published this past July in The Journal of Clinical Endocrinology & Metabolism asked, “Can machine learning transform the diagnostic approach to congenital disorders of adrenal steroidogenesis?” Jani Liimatta, MD, PhD, of the Institute of Clinical Medicine at the University of Eastern Finland in Kuopio, wrote the paper opining on another study published in […]The post Rise of Machine
    September 7, 2026
    Realizing the Promise: Artificial Intelligence in Endocrinology

    Realizing the Promise: Artificial Intelligence in Endocrinology

    Artificial intelligence (AI) is steadily moving from novelty to necessity in medicine, and endocrinology is no exception. The ENDO 2026 session “Artificial Intelligence in Endocrinology: Practical Uses, Lessons Learned, and What Comes Next” showed attendees that AI is here, and those who wait too long to engage with it may find themselves playing catch-up. At […]The post Realizing the Promise: Art
    August 7, 2026
    Moving Forward: The Future of GLP-1 Therapies

    Moving Forward: The Future of GLP-1 Therapies

    The Endocrine Society recently held a virtual Science Writers Conference dedicated to the current landscape and future horizons of GLP-1 therapies, examining new oral formulations and dual and triple agonists. Endocrine News caught up with the two experts who spoke at the conference — Priya Jaisinghani, MD, DABOM and Mehmet Furkan Burak, MD – to learn what’s next for these medications and what the
    March 11, 2026
    Side Effects: Endocrine Society Journals Look at GLP-1RAs and the Positive and Negative Unintended Impacts

    Side Effects: Endocrine Society Journals Look at GLP-1RAs and the Positive and Negative Unintended Impacts

    As the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) expands, so too does our knowledge of just what all these medications can do. GLP-1RAs have now been shown to reduce consumption of alcohol and drugs, even treating addictions to gambling and sex, but these medications can also potentially lead to rare but fatal complications of which endocrinologists should be aware.Glucagon-like
    February 19, 2026
    Tirzepatide Improves Blood Sugar Control in Children Aged 10-17 Years with Type 2 Diabetes

    Tirzepatide Improves Blood Sugar Control in Children Aged 10-17 Years with Type 2 Diabetes

    New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both.The study (the SURPASS-PEDS trial), led by Tamara Hannon,
    December 2, 2025
    Staying in Control

    Staying in Control

    A recent clinical trial reveals encouraging news for a Cushing’s disease treatmentA poster from ENDO 2025 showed that osilodrostat provides sustained clinical benefits in Cushing’s patients who experienced positive outcomes by the end of the treatment period. Richard Auchus, MD, PhD, discusses how the data reinforces the drug’s use, which was well-tolerated for extended periods.Not that long ago,
    October 7, 2025
    AI in the Family

    AI in the Family

    Revolutionary artificial intelligence applications transform endocrine disease detection and managementAttendees at ENDO 2025 in San Francisco were all buzzing about the Elangovan family of Houston, Texas. That’s because high school-aged siblings, Ramya and Kavin, were presenting their research into how artificial intelligence (AI) could change the way certain endocrine disorders were diagnosed an
    October 2, 2025
    The Hormone Games

    The Hormone Games

    In the arena of endocrine research, high-tech tools are the new power players.In the ever-evolving landscape of endocrinology, the laboratory remains the engine of innovation. From uncovering new hormonal pathways to refining diagnostics and therapeutics, research labs are increasingly dependent on tools that offer speed, sensitivity, and scalability. In the complex environment of endocrine resear
    July 31, 2025
    Should  SGLT2 Inhibitors Be Stopped Before Emergency Surgery?

    Should  SGLT2 Inhibitors Be Stopped Before Emergency Surgery?

    A new study entitled “Postoperative Outcomes Among Sodium-Glucose Cotransporter 2 Inhibitor Users” published in JAMA Surgery calls into question the current guidelines advising doctors to pause a widely used class of diabetes drugs—sodium-glucose cotransporter 2 inhibitors (SGLT2i) — before surgery. The findings suggest the risk of developing postoperative euglycemic ketoacidosis (eKA), a serious
    July 1, 2025
    Pharma Fridays – June 27, 2025

    Pharma Fridays – June 27, 2025

    An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. *Results from AMGEN’S Phase 2 Obesity Study OF Monthly MariTide Presented at The American Diabetes Association 85th Scientific SessionsMariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Sig
    June 27, 2025
    Contact
    1 (888) 363-6762
    Cookies
    Reselect cookie settings
    Community engagement platform by Hivebrite.